<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0004027'>Trisomy</z:mp> 21 as an acquired clonal chromosome change has been described in 642 of the 10,625 human <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with chromosome aberrations known from the cytogenetic literature </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 590 of the 642 cases (92%) are <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> and malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The incidence of <z:mp ids='MP_0004027'>trisomy</z:mp> 21 is similar (4.1%-6.7%) in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, and malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; it is substantially higher (14.8%) in <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="3" pm="."><plain>In most cases, the extra chromosome 21 is present together with other numerical and/or structural changes </plain></SENT>
<SENT sid="4" pm="."><plain>Acquired <z:mp ids='MP_0004027'>trisomy</z:mp> 21 is the only karyotypic abnormality in only 0.4% </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0004027'>Trisomy</z:mp> 21 has never been reported as the sole anomaly in a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The cytogenetic literature contains information on 62 patients with constitutional <z:mp ids='MP_0004027'>trisomy</z:mp> 21 and a malignant disorder in which the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells have been analyzed by banding techniques </plain></SENT>
<SENT sid="7" pm="."><plain>Thirty-four of the 62 patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 16 had ALL, and 2 had <z:hpo ids='HP_0011009'>acute</z:hpo> undifferentiated <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The 52 leukemic <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> (DS) cases account for 1.4% of the total <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, an overrepresentation that parallels the generally increased risk of <z:hpo ids='HP_0001909'>leukemia</z:hpo> development in DS </plain></SENT>
<SENT sid="9" pm="."><plain>Sixty-three percent of the ALL patients and 79% of those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> had additional changes superimposed on constitutional <z:mp ids='MP_0004027'>trisomy</z:mp> 21 </plain></SENT>
<SENT sid="10" pm="."><plain>These included several of the characteristic primary <z:hpo ids='HP_0001909'>leukemia</z:hpo>-associated aberrations: 5q-, 7q-, +8, and t(8;21) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and t(1;19), t(4;11), 6q-, and 14q + in ALL </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, it seems that the pattern of acquired karyotypic changes is similar in patients with DS and in individuals with a <z:mpath ids='MPATH_458'>normal</z:mpath> constitutional karyotype </plain></SENT>
</text></document>